ANIP as reported
ANI Pharmaceuticals, Inc. reported $924M of revenue over the trailing twelve months, +37% on the year before. 11 reported series are charted on this page, each one as filed.
$924M
Revenue, trailing twelve months · to Q1 2026 · +37% against the twelve months before
- Net Income
- $92M
Net Income · −538% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- $191M
Free Cash Flow · +187% year on year · trailing twelve months to Q1 2026
- Op Margin
- 13%
Op Margin · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $924M | +37% | Q1 2026 |
| Net Income | $92M | −538% | Q1 2026 |
| EPS | $3.94 | −410% | Q1 2026 |
| Gross Margin | 61% | n/a | Q1 2026 |
| Op Margin | 13% | n/a | Q1 2026 |
| Net Margin | 9.8% | n/a | Q1 2026 |
| ROE | 9.1% | n/a | Q1 2026 |
| ROA | 3.5% | n/a | Q1 2026 |
| ROIC | 11% | n/a | Q1 2026 |
| Free Cash Flow | $191M | +187% | Q1 2026 |
| P/E | 18.9 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
ANI Pharmaceuticals, Inc. (ANIP) - Revenue & ProfitRevenue & ProfitANI Pharmaceuticals, Inc. (ANIP)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com
Drug Manufacturers - Specialty & Generic
Ranks #10 of 28 by Smart Score